Market closedNon-fractional
REGENXBIO/RGNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About REGENXBIO
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Ticker
RGNX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Rockville, United States
Employees
344
Website
www.regenxbio.com
REGENXBIO Metrics
BasicAdvanced
$709M
Market cap
-
P/E ratio
-$5.87
EPS
1.34
Beta
-
Dividend rate
Price and volume
Market cap
$709M
Beta
1.34
Financial strength
Current ratio
3.589
Quick ratio
3.218
Long term debt to equity
31.967
Total debt to equity
43.66
Interest coverage (TTM)
-42.77%
Management effectiveness
Return on assets (TTM)
-23.60%
Return on equity (TTM)
-60.80%
Valuation
Price to revenue (TTM)
7.351
Price to book
1.82
Price to tangible book (TTM)
1.82
Price to free cash flow (TTM)
-3.209
Growth
Revenue change (TTM)
-20.90%
Earnings per share change (TTM)
-6.03%
3-year revenue growth (CAGR)
-17.74%
3-year earnings per share growth (CAGR)
23.00%
What the Analysts think about REGENXBIO
Analyst Ratings
Majority rating from 11 analysts.
REGENXBIO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$16M
-29.73%
Net income
-$63M
0.80%
Profit margin
-405.76%
43.44%
REGENXBIO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.66
-$1.41
-$1.43
-$1.38
-
Expected
-$1.39
-$1.52
-$1.27
-$1.26
-$1.29
Surprise
19.86%
-7.10%
12.55%
9.61%
-
REGENXBIO News
AllArticlesVideos
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
PRNewsWire·2 days ago
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
PRNewsWire·1 month ago
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
PRNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for REGENXBIO stock?
REGENXBIO (RGNX) has a market cap of $709M as of July 27, 2024.
What is the P/E ratio for REGENXBIO stock?
The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of July 27, 2024.
Does REGENXBIO stock pay dividends?
No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next REGENXBIO dividend payment date?
REGENXBIO (RGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for REGENXBIO?
REGENXBIO (RGNX) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell REGENXBIO stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.